Table 1 Overall clinical features of cases included in the study
Variable | Baseline distribution in cohort |
|---|---|
Sample | |
Sample size for sequencing | 418 |
Sample size for outcome data | 418 |
Median (range) follow-up | 5.4 (0.1–11.5) years |
Demographics | |
Sex | |
Male | 243 (58.1%) |
Female | 171 (40.9%) |
NA | 4 (1%) |
Age, mean ± SD | 56.6 ± 8.4 years |
Biochemical | |
β2 microglobulin, mean ± SD | 7.8 ± 9.6 (mg/L) |
MM staging | |
ISS I | 150 (35.9%) |
ISS II | 102 (24.4%) |
ISS III | 86 (20.6 %) |
NA | 80 (19.1%) |
Treatment | |
VD-HDM | 266 (63.6%) |
VTD-HDM | 53 (12.7%) |
VAD-HDM | 67 (16.0%) |
MPV/KMP | 5 (1.2%) |
MPT | 10 (2.4%) |
RD | 5 (1.2%) |
SMM | 1 (0.2%) |
NA | 11 (2.6%) |
Outcome | |
Relapse | 359/418 (85.9%) |
Death | 202/418 (48.3%) |
